Navigation Links
International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis

WORCESTER, Massachusetts, July 08, 2007 /PRNewswire/ --

- ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate prophylaxis to Prevent VTE

Venous thromboembolism (VTE) risk is high among hospital patients and most of these at-risk patients are not protected with adequate prophylaxis according to data from the international ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study presented today at the XXIst International Society on Thrombosis and Haemostasis (ISTH) congress in Geneva.

VTE is a preventable disease which contributes significantly to morbidity and mortality among patients hospitalized for acute medical and surgical illnesses. Many complications and deaths due to VTE could be prevented using thromboprophylaxis as recommended by evidence based guidelines, but some studies have shown that there is a gap between evidence and practice in the hospital setting. Lack of awareness and uncertainty about the prevalence of patients at risk for VTE are among the major reasons accounting for this gap (1, 2). To date, there has been no large international study performed in hospitals selected at random around the world to evaluate VTE risk and prophylaxis practice globally.

ENDORSE collected data on more than 60,000 patients who were surveyed across 358 acute care hospitals randomly selected in 32 countries, encompassing 5 continents. All participating hospitals followed the same standard multinational protocol to survey the patients present in the wards.

The main objectives of ENDORSE were to assess the prevalence of VTE risk in the acute hospital care setting and to determine the proportion of at-risk patients who receive recommended prophylaxis using the d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
6. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

Post Your Comments:
(Date:11/20/2009)... LAKES, N.J., Nov. 20 BD...day announced the completion of its acquisition of...any that develops and manufactures molecular diagn...y 2009, BD and HandyLab announced an exclusive agr...ar assays on the HandyLab Jaguar(TM) platform, the...
(Date:11/19/2009)...GHAM, Ala., Nov. 19 BioC...announced the pricing of a public offering of 5,00...e, resulting in gross proceeds of $48.75 million. ...ursuant to an effective shelf registration stateme...ge Commission. BioCryst has also granted the unde...
(Date:11/19/2009)... VIEW, Calif., Nov. 19 A...nced today that its corporate presentation will be... Health Care Conference on Wednesday, December 2, ...will be webcast from The New York Palace Hotel in ...Alexza President and CEO. ,, To access the li...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Fluorescent probes may permit monitoring of chemotherapy effectiveness Stanford study shows 51519 1Fluorescent probes may permit monitoring of chemotherapy effectiveness Stanford study shows 51519 2Fluorescent probes may permit monitoring of chemotherapy effectiveness Stanford study shows 51519 3Promising hematologists begin year long program to pursue careers in clinical research 51517 1Promising hematologists begin year long program to pursue careers in clinical research 51517 2Grant encourages protected research time for medical fellows 51515 1
(Date:11/20/2009).../GYN warns against the new breast cancer recommend...Task Force. These guidelines may be cost-effective...is it wrong to be safe than sorry? , ...k Force recommendations, published in the current ...off a firestorm in the medical community. Major me...
(Date:11/20/2009)... Missouri state employees in the So...w have the option to choose Mercy Health Plans tha...ri Consolidated Health Care Plan (MCHCP) and Mercy...al Missouri regions include the following counties...ouglas, Greene, Hickory, Howell, Jasper, Laclede, ...
(Date:11/20/2009)...ov. 20 California minority advocac...es, The Wall/Las Memorias, Latina Breast Cancer Ag...d the Real Medicine Foundation today sent a letter...ny to reconsider harmful and discriminatory covera...fically calls for an end to the practice of step t...
(Date:11/20/2009)...swire/ -- Today, iconic denim brand DKNY JEANS a...of a capsule gift giving collection offered exclus...This collection is inspired by and designed for St...d Giving® Program, a holiday fundraising and...give thanks for the healthy kids in your lives and...
(Date:11/20/2009)...RNewswire-USNewswire/ -- The US government reporte...get enough food to eat. This startling statistic ...e rapidly aging into poverty. "Forced retirements...an many have incomes that no longer cover the basi...omen are particularly vulnerable," said Kate White...
Breaking Medicine News(10 mins):Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 3
..., S.C., Dec. 18 DuPont has selected,its Cooper Ri...stment it,recently announced to significantly expa...r(R) para-aramid brand fiber for industrial and mi...ion of,a new Kevlar(R) fiber facility. It is expec...
...Firm to Celtic Pharma Launched, NEW YORK and U.S....Management L.L.L.P. ("Celtic Therapeutics") announ...n Evans-Freke as a General Partner,in Celtic Thera... to operate on a significantly larger scale than,C...
...GTON, Dec. 18 Microloans to the poor,around the w...illion just,nine years ago, according to a report ... an initiative of RESULTS Educational Fund. The dr...amilies in 2006, just shy of the Campaign,s goal o...
...K (Dec. 17, 2007) -- The Leon Levy Foundation has ...sbyterian Hospital/Weill Cornell Medical Center in...h into two little-understood neurological disorder...progressive neurologic disorder in older adults th...
... Dec. 18, 2007 UT Southwestern Medical Center re...ndex criteria for obesity surgery often excludes a... disease. , The study, appearing in the December...(BMI) and cardiovascular disease as it relates to ...
...al agent works differently than statin medications...ws) -- A new kind of drug designed to lower levels...l and reduce heart disease risk has proved safe an... 24 moderately overweight people with high LDL lev...
Other Medicine News:Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 2Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 3Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 4Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 5Health News:Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner 2Health News:Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner 3Health News:Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner 4Health News:Controversial New Report Details Successes and Challenges as the Microcredit Movement Escalates Its Battle With Poverty 2Health News:Controversial New Report Details Successes and Challenges as the Microcredit Movement Escalates Its Battle With Poverty 3Health News:$1.4 million grant awarded to study 2 little-understood neurological disorders 2Health News:BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest 2Health News:New Type of Cholesterol-Lowering Drug Shows Promise 2
...any special order products are offered as 1-piece ...modular instruments may be customized with handles...ulation and flush ports. Many standard patterns ar...ations may affect delivery times. , Please Note: ...
...ntroducing the widest offering of single-use instr...lengths and long 43cm lengths for Bariatric Surger... Extended insulation covers the pivot points to re...m universal cord, which eliminates gapping at conn...
...he 5mm AEM Laparoscopic Instruments incorporate a ...ents are shielded and monitored to prevent stray e...ment caused by insulation failure or capacitive co... protective shield built into all AEM Instruments ...
...he 5mm AEM Laparoscopic Instruments incorporate a ...ents are shielded and monitored to prevent stray e...ment caused by insulation failure or capacitive co... protective shield built into all AEM Instruments ...
Medicine Products: